Disclaimer
The alfapump® system is not currently approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see www.poseidonstudy.com.
The DSR therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed.
The DSR therapy is not currently approved for clinical research in the United States or Canada. There is no link between the DSR therapy and ongoing investigations with the alfapump® system in Europe.
Chief Executive Officer
“Sequana Medical is at an exciting phase in its development with clear ambitions to accelerate its commercial growth and innovation. We continue to invest in our alfapump® and DSR® technologies to bring these innovative treatment options to a broader patient group and address important unmet medical needs, while creating value for shareholders.”
ISIN: XXXXXXXXXXXXX-XXXX Updated at 11:05:33
XXXXX.XX
For more information, please consult Euronext
September 19, 2024
